The state of Oregon currently has 244 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Portland, Eugene, Medford and Clackamas.
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Cancer
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Kaiser Permanente Northwest, Portland, Oregon
Conditions: Colorectal Cancer
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Recruiting
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks. Enzalutamide will be continued at dose of 160 mg orally every day. Patients who have neither rapid disease progression or disease response will undergo a fecal microbiota transplant, have a second biopsy (if medically feasible), and be re-treated with pembrolizumab.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/21/2022
Locations: VA Portland Health Care System, Portland, Oregon
Conditions: Prostate Cancer, Prostate Cancer Metastatic
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Recruiting
Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/19/2022
Locations: VA Portland Healthcare System, Portland, Oregon
Conditions: Prostate Cancer